PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 4 al., 2018; Ho, et al., 2014; Lazarus et al., 2016; Xie et al., 2016) . Increased risk for developing gastric tumors and gastric carcinoma in association with long-term PPI use is yet another concern addressed in recent research. Jianu, Fossmark, Viset, Qvigstad, Sordal, Marvik et al., (2012) presented two case studies which showed hypergastrinemia secondary to PPI therapy, concluding that enterochromaffin-like (ECL) carcinoids could arise from long term PPI use, as occurred in the cases they reported. Song, Zhu and Lu (2014) concluded in their systematic review that patients taking PPIs long-term have an increased possibility for experiencing simple or focal ECL hyperplasia, without certainty of the clinical significance or correlation to the development of corpus gastric atrophy, intestinal metaplasia or overall increased risk for the development of pre-cancerous gastric lesions. A case study of iron deficiency anemia was reported as severe in nature, in association with long-term PPI use (Dado, Loesch, & Jaganathan (2017) . A large cohort study of veterans by Xie et al. (2016) cited excess risk of death among PPI users, including those taking PPIs long-term without necessity, compared to those taking histamine receptor agonists (H2RAs).
Many patients take PPIs for years without reasons and are reluctant to stop use (Avraham & Biglow, 2018; Farrell, B. et al., 2017; Naunton, M. et al., 2018; Reeve et al., 2015; Thompson, Black et. al., 2017; Xie, et al., 2016) . Thompson, Black et al. (2017) performed a scoping review of seven survey studies, four qualitative studies and one randomized control trial. These researchers found only one study which evaluated patient preferences, with respect to decreasing or ceasing PPI use. They cited that patients prioritized adequate symptom control the most and had anxiety about return of symptoms with medication dose reduction. Further, Thompson, Black et al. noted that patients are willing to discuss the option of continuing PPI use or try to reduce their PPI use, but held divergent attitudes about reduction. Thompson, Black et al. (2017) PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 5 cited evidence that decreasing PPI dosing is an individual decision based on each person's preferences. They recommended including patient input into the decisions to change doses. Thompson, Black et. al (2017) cited that many persons were willing to continue PPI use at lowest doses possible for symptom control, rather than completely ceasing use. Lazarus et. al (2016) found in a population-based cohort study that twice daily PPI use was associated with greater risk for chronic kidney disease than once daily long-term use. Economic savings of limiting chronic PPI use correlates to decreases in side effect related costs and medication cost reduction when the medication is taken as needed, without ongoing full dosing . Naunton et al., (2018) concluded in a review of PPI use between many nations that the medication class is still used without necessity in many situations world-wide, warranting prioritization of more specific de-prescribing efforts.
PCPs are advised by gastroenterologists to de-prescribe patients with no exclusion criteria for cessation after up to 8 weeks of use (Avraham & Biglow, 2018; Farrell, et al., 2017) , with minimal guideline support (Avraham & Biglow, 2018; Farrell, et al., 2017; Reeve, et al., 2015) . Thompson, Black et al., (2017) cited a plethora of findings exist that few patients require therapeutic care with long term PPI use (2017) . De-prescribing constitutes multiple options: sudden abruption, tapering to half dosing and then as needed use or substituting use at the time of de-prescribing with H2Ras to control rebound GERD symptoms (Avraham & Biglow, 2018; Farrell, et al., 2017; Reeve, et al., 2015; Thompson, Black, et al., 2017) . Tapering and medication substitution, are supported by the evidence. (Avraham & Biglow, 2018; Farrell, et al., 2017; Reeve, et al., 2015; Thompson, Black, et al., 2017) . Regardless, patients do sometimes abruptly cease long term use of PPIs and report symptoms of rebound acid hypersecretion (RAHS).
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Evidence does not support abrupt cessation Naunton et al., 2018; Reeve, et al., 2015; Thompson, Black et al., 2017) , as RAHS may inhibit PPI cessation maintenance in de-prescribed long-term users.
Lifestyle and dietary changes have been encouraged to support GERD management.
Zolvan, Hu, and Greenberg cited (2017) that prior studies promoting standard reflux precautions have not resulted in decreasing GERD incidence. Lifestyle precautions, such as avoiding heavy late-night meals, intake of spicy foods, high acid containing foods, tobacco, alcohol and caffeine have been promoted by health care providers to reduce GERD symptoms. Such recommendations constitute empirical treatment (Meining & Classen, 2000) . Lifestyle and dietary recommendations have not been found in the evidence to play a role in the development, management or progression of GERD, except for in studies with very small numbers of patients (Meining & Classen, 2000) . Ness-Jensen, Hveem, El-Serag, and Lagergren (2016) performed a systematic review of the evidence to update lifestyle and dietary recommendations found helpful for GERD symptom management. Weight loss was found to be useful, as reported in two randomized control trials (RCTs), as well as tobacco cessation (Ness-Jensen et al., 2016) . NessJensen et al. (2016) also cited that avoidance of late-night meals and elevation of the head at nighttime as effective for managing nocturnally occurring GERD symptoms. Only these four lifestyle changes are supported by updated evidence as effective (Ness-Jensen et al., 2016) .
Symptoms of laryngopharangeal reflux have been previously addressed with long-term PPI use (Zolvan, Hu, & Greenberg, 2017) . Changing over to a plant based Mediterranean Diet and use of alkaline water with standard reflux precautions was demonstrated in a retrospective cohort study of two treatment cohorts (Level IV evidence) with subjects of a median age of 60, PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 7 to be much more effective for limiting symptoms of laryngopharangeal reflux than long-term PPI use (Zalvan, Hu, & Greenberg, 2017) .
PCPs may rely on experience in choosing de-prescribing methods (Thompson, Black et al., 2017) . Patients report valuing symptom control and angst about RAHS following PPI cessation (Thompson, Black et al. 2017 ). Use of de-prescribing guidelines help patients share in decision-making for tapering and cessation in support of better outcomes (Thompson, Black et. al 2017) . Prescribers must consider patient values and preferences (Thompson, Black et al., 2017) . In a veteran outpatient population in the San Diego Veterans Administration Healthcare System (SDVA), the usual de-prescribing care for appropriate patients is performed by PCPs.
PPIs are typically de-prescribed after 4 to 8 weeks of use, per institutional pharmacy recommendations implemented in 2015. Patients are supposed to be advised by PCPs to seek follow up care if their GERD symptoms return. Tapering is recommended, without specification or use of parameters or an evidence-based guideline protocol to direct regimens previously found effective. Substitution with formulary H2RAs, such as famotidine hydrochloride and ranitidine hydrochloride, are suggested as optional for use at the time of de-prescribing.
Up to Date Evidenced-Based PPI De-prescribing Guideline Use vs. Usual Care
Up to date de-prescribing protocols recommend closer provider driven follow up care than is presently offered SDVA veterans. Avraham and Biglow (2018) developed a guideline for PPI de-prescribing by reducing the dose in half every 3 weeks and then changing the frequency to every other day of use over 3 weeks in a pilot study of ten elderly residents de-prescribed in a nursing home. Follow up assessments were recommended by a clinical pharmacist every 3 weeks during de-prescribing, over the course of 12 weeks (Avraham & Biglow, 2018) . This guideline PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 8 requires four follow up visits or phone call assessments during tapering (Avraham & Biglow, 2018) .
Previously, in 2013, Reeve et al. developed a PPI de-prescribing guideline in Australia that was published in 2015. Fifty-seven PPI users were recruited for a feasibility study and six of these users participated and achieved successful cessation of use for minimally 6 months.
Tapering was recommended by reducing PPI dosing in half with use of a symptom action plan to add doses as needed or to return to the prior dose taken to alleviate onset of any associated severe RAHS during de-prescribing (Reeve, et al., 2015) . Patients tapered with call backs every 2 weeks during de-prescribing (Reeve, et al., 2015) . Ten-minute pharmacy led phone call follow up interventions every 2 weeks during 6 weeks of de-prescribing were conducted and additional phone calls made 6 weeks after de-prescribing were completed with subsequent call backs 6 months following de-prescribing, to evaluate for ongoing cessation of use (Reeve, et al., 2015 ).
An average of 4.3 phone calls were made to six participants who were de-prescribed in their feasibility study of use of a guideline (Reeve, et al., 2015) . Total time used by health professionals to de-prescribe each patient constituted about 1.5 hours per patient, as presented in their 2013 conference poster (Reeve, et al., 2015) .
The usual SDVA Healthcare System de-prescribing care since 2015 is for PCPs to stop ordering PPIs after 8 weeks by tapering the dose and substituting with H2RAs. Very limited specified de-prescribing guidance is offered. Exclusion criteria for de-prescribing is incomplete.
Tapering instructions do not include recommendations for follow up to determine efficacy. SDVA PCPs are not specifically guided to seek testing for helicobacter pylori antibodies or to order endoscopies after de-prescribing patients who report ongoing GERD symptoms following de-prescribing failures. Congress of Gastroenterology in 1999. The classification system uses endoscopic findings and circumferential measurements to objectively determine the severity of GERD by enumerating and measuring erosions in mucosal breaks of < or > 5mm in size and the degree of extension of erosions between the tops of two mucosal folds apiece (Lundell, et al., 1999; Sami & Ragunth, 2013) . When used in clinical decision-making for de-prescribing, L.A. Classification of GERD may ensure patients with severe GERD are not inappropriately de-prescribed off long-term PPIs.
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The Farrell et al. 2017 PPI De-Prescribing Guideline, published in Canada, applies the internationally used L.A. Classification of Oesophagitis, which makes it a preferred guideline. It is supported by objective evidence to determine criteria for use in de-prescribing practices. No team-driven follow up is standardized for SDVA PCPs to support evaluation for prolonged PPI cessation success in the SDVA. Two patient care instruction sheets were made available by the Department of Pharmacy for PCPs to copy and give to patients in 2015. They cite overutilization of PPIs, associated risks, and recommendations for foods to choose and avoid for management of GERD. Many patients are not re-evaluated until they return for routine care
and are found to have continued or resumed taking PPIs, sometimes by purchasing them over the counter (OTC).
Patients report resuming PPIs due to their efficacy, even as risks may outweigh benefits for Many long-term users (Naunton, et al., 2018; Farrell, et al., 2017; . A primary care (PC) team driven follow up mechanism to reassess patient symptoms at intervals following de-prescribing is supported by newer evidence Naunton, et al., 2018) . Patients who continue to take very costly PPIs after de-prescribing may miss PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 11 opportunities to receive timely endoscopies and biopsies, which diagnose helicobacter pylori antibodies, Barrett's esophagitis, or esophageal cancer, which warrant different treatment.
Few patients taking PPIs long term meet criteria for having a history of ulcer and/or grade C or D GERD, which are conditions the evidence supports which would warrant continuing their PPI use . PCPs sometimes abruptly discontinue PPIs, after more than 4 weeks of continuous use. Evidence shows abrupt PPI cessation is less effective than tapering to mitigate rebound acid hypersecretion symptom (RAHS) severity (Naunton, et al., 2018) . Persons abruptly ceasing PPI therapy may therefore be understood to be more apt to resume long-term PPI therapy following de-prescribing, as they are more likely to develop severe RAHS following de-prescribing without first tapering use (Boghossian, et al., 2017) .
Patients may then decide to purchase PPIs over the counter (OTC) to privately manage their own symptoms. Since PPIs became available for purchase OTC years ago, cessation falls into the hands of the patient, who will make lifestyle changes recommended by the evidence or face risks associated with excessively blocking symptoms of acid reflux by continuing use.
Description of EBP Project, Facilitators and Barriers
A more structured and simplified approach to de-prescribing PPIs can improve successful de-prescribing of PPIs in appropriate situations. Implementation of an evidence-based practice (EBP) PPI de-prescribing guideline, developed by a team of experts utilizing grading of recommendations assessment, development and evaluation (GRADE) by a team to guide recommendations for de-prescribing PPIs (Farrell et al., 2016) Peer led education, as a strategy to promote improved practice, is supported by evidence.
A Level IV longitudinal study showed that mandatory peer to peer consultation used by radiologists reviewing radiology medical management reduces costs by limiting inappropriate us of high cost imaging studies (Ip, Schneider, Seltzer, Smith, Dudley, Menard, & Khorasani, 2013) . A separate scoping review of the efficacy of peer-led education to improve patient safety in four separate studies was reviewed for relevance (Walpola, McLachlin & Chen; . A peer to PCPs (MDs and NPs) and to registered nurses (RNs) functioning on teams in primary care
(PC) was determined to be similarly capable to promote changes in programs or routine care to improve de-prescribing of PPIs to reduce costs with improved outcomes.
The PPI De-prescribing Guideline this NP peer (author) selected to try to implement into improve practice in this primary care veteran population constitutes Level VII evidence , as it was constructed by a multidisciplinary group of experts in Canada. Its development was based on evidence obtained from few Level I meta-analyses of RCTs (Boghossian, et al., 2017; Gatta et al., 2007) and cohort studies (Avraham & Biglow, 2018; Gualtero et al., 2017; Ho, et al., 2014; Khan, et al., 2018; Lazarus, et al., 2016; Naunton, et al., PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 14 2018; Xie, et al., 2016; Zalvan, et al. 2017) . One meta-synthesis (Level VI evidence) was incorporated (Thompson, et al., 2018) . Canadian based de-prescribing guideline aims to improve effective PPI de-prescribing with simple and specific tapering instructions and follow up care to mitigate patient safety risks and unnecessary costs associated with PPI de-prescribing failures. GRADE criteria and checklists were used in its development.
Its simplicity and specificity lend its optimal use for piloting with consistency in a primary care setting with minimal available team driven follow up phone call care availability. The NP selected guideline of choice was developed to promote and support PCPs beginning to address PPI de-prescribing for patients engaged in unnecessary, long-term use in Canada.
Evidence Based Project Model
The Iowa Model (Melnyk & Fineout-Overholt, 2015) was used for this practice change which was driven by two triggers, new knowledge and the spirit of inquiry. The new knowledge guiding a change in care, de-prescribing PPIs for appropriate patients, is supported primarily by retrospective cohort studies in the evidence. The spirit of inquiry is a separate trigger driven by the PCP trying to configure the best practice means to reach the outcome of effective cessation of use of PPIs for the patients who do not need to take them long term and may be at risk for adverse outcomes on them. De-prescribing PPIs is presently recognized by the Department of Medicine and Department of Pharmacy as a patient safety and cost reduction priority in the SDVA Healthcare System. The Iowa Evidence Based Model was incorporated into this DNP project, as it supports a team approach to problem solving.
Proposed Evidenced-based Solutions, Project Development and Implementation Timelines
To resolve the problem with the usual care, searches were made in CIANHL, Ovid, PubMed and Cochrane data bases of PPI side effects. Level I, II and IV evidence was found PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 15 searching key words: "proton pump inhibitors," and "clostridium difficile causes." Mostly Level IV evidence was used in support of recommendations to de-prescribe PPIs due to side effects following long term use since some Level II evidence (RCTs) did not reveal sufficient evidence of side effects of use associated with early onset of dementia or gastric cancer. Level IV evidence in large cohort longitudinal and observational studies (Ho, et al., 2014; Lazarus, et al., 2016; Xie et al., 2016; Zalvan et al., 2017) was overall much stronger in support of deprescribing PPIs. Thirty-three research articles were reviewed. Peer led education and coaching literature was searched for applicability between sites for evidence-based practice changes.
The Five A's, as originally published by Fiore, Hatsukami, and Baker (2001) for use for tobacco cessation treatment) was located. Use of the Five A's for patient counseling in separate situations (Glasgow & Miller, 2006) was identified, as the tool was also used by Glasgow and by PC nursing staff who would address follow up using the Five A's instrument in a pilot that was proposed to be launched following education of the Canadian PPI De-prescribing Guideline and competing guidelines. Kirkpatrick's Four Levels (Kirkpatrick, 1994; Kirkpatrick & Kirkpatrick, 2016) were reviewed in the original format developed by Don Kirkpatrick (1959) and as published in 1993. The Four Levels, as updated for use by Kirkpatrick's son and daughter in-law (Kirkpatrick & Kirkpatrick, 2016) for training and evaluation were used to measure success of the QI education EBP project. The Four Levels (Kirkpatrick & Kirkpatrick, 2016) was utilized as an instrument to measure the success of peer led training. Specific measurement outcomes to assess the efficacy of the education could be determined by actual PCP behavior changes following education. 
Project Approval

Education Implementation to Translate Evidence Based Practice Guideline into Use
Towards a goal of attaining a consensus from PCPs to pilot the new algorithm in PC, a series of steps was used to enhance provider willingness to change from the usual care. This author, a NP peer, proposed to introduce and educate PCPs to the 2017 evidence-based practice (EBP) PPI De-prescribing Guideline developed in Canada (Ip et al., 2015) .
Provider willingness to change de-prescribing care practices was assessed throughout the education project in four process steps. First, a twelve question Likert survey pretest was conducted by the NP to assess the usual care for de-prescribing PPIs at two similar primary care practice sites in the San Diego VA Healthcare System. Fifteen PCPs participated in the survey.
Next, peer led education about the 2017 EBP PPI de-prescribing algorithm developed in Canada by a team of five health professionals (one gastroenterologist, one family physician, and three pharmacists) and five nonvoting members was introduced . A proposal to change from the usual care to translate guideline use into practice to improve care in an appropriate veteran primary care population was made. Discussions were initiated with five on site PCPs at the SDVA SVOPC PC site at routine monthly provider meetings, over the course of
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3-months duration. The five PCPs who participated in peer-led education comprised four board certified internal medicine physicians and one board certified Master's degree prepared NP).
Following departmental and VA Healthcare IRB approval to conduct this education evidencebased quality improvement (QI) project, targeted articles selected from a formal review of the literature were shared at each of three monthly-provider meetings; they were introduced by the NP peer PCP (author).
After interest was ascertained at the first meeting, the NP peer electronically sent several select publications to participating PCPs onsite to separately review, in order to garner more understand of the breadth of PCP concerns and questions, which could be addressed prior to and during the second provider meeting. Selected articles discussed side effects of chronic PPI use Nehra, Alexander, Loftus, & Nehra, 2018; Reeve, et al., 2014; Thompson, Black et al., 2017) and problems with PCPs de-prescribing with abrupt cessation, which typically did not result in successful de-prescribing of PPIs for many patients taking them long term without need . Education lasted about forty-five minutes at each of three meetings.
In between meetings, three PPI evidence based de-prescribing guidelines (Avraham & Biglow, 2018; Farrell, et al., 2017 & Reeve, et al., 2015 were introduced by electronic mail to PCPs for critical evaluation, to determine which one would best meet the needs of a veteran population to improve de-prescribing care and outcomes. PCPS learned that each of the deprescribing guidelines introduced to them recommended tapering PPI use prior to cessation and team driven follow up of patients to ascertain cessation maintenance. Supplemental evidence to support tapering used in the development of each guideline was provided with each publication. concurrently being studied at all local VA PC sites, due to extensive system wide nationally driven demands for benchmark satisfaction of opioid de-prescribing and other mandated activities for satisfactory performance measurements. PCPs noted that RN support was already being geared toward these activities and may inhibit RN availability to launch a pilot for guideline required patient call backs to fully implement translation of the guideline at all levels.
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During provider education, the NP peer concurrently surveyed registered nurse (RN) interest in participating in a pilot after completion of the education project that would require PCP teams to call patients only at 4-and 12-week intervals following de-prescribing patients off of PPIs. 12 month follow up could be done by PCPs at visits. The Department of Pharmacy had indicated prior to IRB approval that resources were not available to release a pharmacist to perform the call backs for up to fifty veterans if a pilot were later conducted, as up to one hundred call backs or follow up visits could be required. Funding was not available to support pharmacy participation. Seven RNs participated in two separate meetings for the NP peer leading the education to ascertain their willingness to participate in follow up phone calls to veterans. All
RNs expressed interest and concurrently cited concerns other nationally driven priorities for care
as impeding with their availability to support phone call follow up during work hours.
The RN manager attended the second meeting and expressed concern about extending RN resources to promote implementation of guideline use. She cited organizational prioritization of national benchmark goals teams were required to assist providers to achieve, in order to reach system-wide mandated performance measure satisfaction criteria. Regardless, she supported the QI project for a pilot study if the RNs found a means for feasibility. One RN expressed interest in participating in a pilot on a smaller scale, after work hours, stating she needed to participate in research to advance for promotion to a higher pay grade before retirement. She asked for structured questionnaires to use for follow-up. The nurse manager of the RNs articulated her support for integration of research to improve care. The RN available after hours to make call backs on her own time was supported to participate outside of normal clinic operation hours. The NP peer (author) cited that perhaps the usual care was partially not resulting in longterm PPI use cessation because patients in the SDVA system were routinely told to follow up themselves if they were not successfully ceasing use of their PPIs after de-prescribing. A concern was that veterans were purchasing PPIs over the counter after de-prescribing, due to their efficacy, instead of reporting recurrence of GERD or RAHS. RAHS could be further evaluated with recommended testing for helicobacter pylori antibodies, and by endoscopies for biopsies and for classification of more serious GERD that might require long term PPI use. Surveillance would occur for patients who sought follow up care or were provided structured PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 22 interval follow up care. Properly identified populations of patients with Grade C or D GERD or persons otherwise not meeting other exclusion criteria for ongoing PPI use could be appropriately prescribed long-term PPI use for planning for appropriate surveillance. Periodic surveillance of esophagitis by endoscopies would not be lost to follow up, consistent with specialist recommendations for severe cases, if only appropriate patients were de-prescribed.
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The NP peer concurrently assessed for provider acceptance and resistance to changing de-prescribing practices with EBP guideline implementation. One to two articles citing Level I, II and IV, VI and VII evidence supporting de-prescribing of PPIs were introduced every 1 to 2 weeks by electronic mail. Two hard copies of each article were brought and disseminated at each of three education sessions to promote a practice change to improve, as triggered by new knowledge. Discussions actively engaged all five participating PCPs into decision-making to change from the usual care. Immediately after the third education session, the same Likert survey pretest was administered as a post-test to the five PCP participants.
Discussion of Results of Pre and Post-tests and Costs
Most PCPs acknowledged in pretesting that up to one third of their patients were still taking PPIs long term after de-prescribing. Only 2 out of 15 PCPs (13.3%) were frustrated with these results. Regardless, all were willing to implement an EBP guideline to improve care and Qualitatively, the PCPs educated in SVOPC explained that after the education there was some uncertainty as to the value of a pilot launch to try the guideline, reporting they were already attending more attentively to de-prescribing and utilizing tapering strategies. One PCP reported he had tapered himself off long-term PPI use following the education intervention. All PCPs reached 100% consensus following education to pilot use of the preferred 2017 Farrell et al.
2017 PPI De-prescribing Guideline. Costs of the education for four attending internal medicine MD salaries and one NP salary and seven RN salaries were estimated at approximately $2,000.00 for three 45-minute education-based meetings with PCPs and RNs to change practice.
Costs for copying articles to disseminate between providers to take with them at meetings was about $10.00 ( Savings of organizational costs for renewing long-term PPI prescriptions and out of pocket patient costs for over the counter use were presumed extensive and were not quantifiable within the scope of this project. Separately, costs related to acute care visits for unknown frequency of related cases of clostridium difficile infections, community acquired pneumonia, osteoporotic fractures or treatment for sequelae of micronutrient deficiencies were not possible to quantify within the scope of this project. Projecting costs for prescriptions and acute care visits for side effects attributable to long-term PPI use could easily be much greater than the $2,010.00 cost of this project, which changed de-prescribing practices to improve care.
Interpretation of Quality of Education Project
The "Four Levels," established in a dissertation by Donald Kirkpatrick in 1959, have come to be known and expanded upon as the gold standard in the literature for assessing training program efficacy. Walpola, McLachlan, and Chen (2018) Kirkpatrick's Four Levels, as expanded upon by Kirkpatrick and Kirkpatrick (2016) , were used to ascertain the quality of this QI project, which aimed to improve patient safety with reduction of long-term PPI use. Level II changes were discovered between pre and post test results, with respect to changes in PCP attitudes and some changes in behavior. A Level III behavior change was specifically cited by a physician who indicated he tapered himself off a long-term PPI he used, subsequent to 3 months of education. Level III evaluations of tapering behaviors changes were revealed in post-tests by PCPs. Several PCPs also provided Level III evaluations of the efficacy of the education and coaching by the NP peer when they explained they might not find ample numbers of subjects still taking PPIs long-term in each of their panels to select to participate in a pilot launch to change practice from the usual care. PCPs indicated that since exposed to and educated about parameters for de-prescribing decision-making and structured tapering options provided in the Canadian PPI De-Prescribing Guideline , they (the providers) were already more conscientiously and selectively de-prescribing PPIs. PCPs also cited a provider burnout study was being performed at the same time as this education project and that they were under pressure to answer to multiple nationally driven performance benchmark measures, such as opioid de-prescribing as priorities. VA Nursing staff burnout was also being evaluated in institutional surveys and was reported high in San Diego in 2018. Long-term PPI de-prescribing had not been set as a national VA priority for PCPs for performance improvement at the time the QI project was completed in San Diego.
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The NP peer (author) presented a poster with costs for the education and improved 
Project Impact and Sustainability
The impact of NP peer led education to PCPs to change de-prescribing PPI practices in a (Kirkpatrick, 1994) .
Strengths and Limitations
The education intervention was partly successful, even without a pilot launch, in that PCPs reported higher tapering practice changes found in the evidence to be more successful for long term cessation. This practice change constituted a measurable level III change validating a successful education project (Kirkpatrick & Kirkpatrick, 2016) . A major limitation was that PCPs did not have staff support for interval patient callbacks at this site. PCPs reported perceptions of high burnout from addressing other priorities under VA national guideline oversight and cited they were tasked to meet prescribed benchmark clinical reminder satisfaction for opioid de-prescribing and other predetermined measures to uphold as priorities.
Implementing EBP guidelines to address changes in practice may take longer in larger systems with more bureaucratic oversight, whereby local clinics do not have the authority to establish newer priorities with limited staff resources.
Conclusion
This NP peer led education project, which informed and coached SDVA PCPs on why and how to use a new EBP de-prescribing guideline, was met with provider willingness to pilot a structured change in practice to promote better outcomes. Naunton et al. (2018) concluded that interventions which show promise for limiting over prescribing of PPIs "include regular medication reviews, facilitated by electronic prompts, and ongoing education of both providers and consumers." This EBP QI project utilized provider education with regular access to coaching from an on-site peer as combined and simultaneously occurring interventions to limit PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 29 inappropriate PPI prescribing practices. Intended outcomes to improve safety and reduce costs were partially met, as some Kirkpatrick (1994) level II and III practice changes occurred.
Provider frustration with the usual care was not a factor found in pre and post-tests to drive willingness to change from the usual care and explore adopting use of an up to date EBP guideline to improve care that would lead patients to expedited sustained cessation of PPI use. A majority of PCPs indicated in pre-tests that they knew many of their patients without a need to take PPIs failed to cease long-term use. In the future, research could be done to qualitatively evaluate the role of factors other than frustration with the usual care, which may promote willingness an openness for practice changes. More patients may complete cessation of unnecessary chronic PPI use and experience fewer side effects and costs associated with long term use following on site education and coaching intervention to support integration of EBP guideline use translation into practice in other settings. Peer-led education and coaching may be considered in other practice situations to promote changes to reduce PCP resistance to change.
Translation of EBP guideline use into clinical practice can be initiated many ways.
Barriers to implementation continue to be explored to bridge the chasm of timely research translation into practice. The NP as a PCP-peer holds a position in the dual role of advanced practice RN and PCP to leverage practice changes by promoting and providing education and coaching to both providers and staff RNs. NPs may be best positioned to initiate interdisciplinary practice changes among three professional groups (i.e., MDs, NPs, RNs) serving in peereducator roles. Careful consideration of priorities which support EBP projects may determine the success of project in larger organizations. Identification of sites which must respond to nationally driven pre-set practice priorities and assessment of the co-existence of PCP burnout prior to starting EBP education projects is essential. Organizations which task providers to first address PEER LED EDUCATION PROJECT TO IMPROVE DE-PRESCRIBING 30 benchmark clinical reminders for satisfaction of their performance measurement, in accordance with top-down decision-making standards set at national levels, may present challenges for NPs to promote EBP peer-led education projects to improve care with staff buy-in.
